Brief: Shanghai Henlius Biotech Permitted To Commence HLX43 Phase 2/3 Trial For Advanced Squamous NSCLC In Japan
04/05/2026 10:05
May 4 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: PERMITTED TO COMMENCE HLX43 PHASE 2/3 TRIAL FOR ADVANCED SQUAMOUS NSCLC IN JAPAN Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln